Few U.S. adults diagnosed with hepatitis C virus infections receive timely treatment with antiviral drugs, the U.S. Centers for Disease Control and Prevention said on Tuesday.
If you are not happy with the results below please do another search
50 search results for:
With an investment valued at up to $1.1 billion, Merck is diving back into Alzheimer’s research through a collaboration with Cerevance.
A group of 23 state attorneys general led by Florida told a federal court on Monday that the U.S. Centers for Disease Control and Prevention (CDC) lacks the legal authority to impose a nationwide transportation mask mandate to address COVID-19.
Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.
Digital therapeutics are transitioning from curiosities to valuable additions to the pharmaceutical armamentarium, but they’re still not common in mainstream medicine.
Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.
The company plans to deliver by next year the order for the IV treatment, which would be a vital option for patients unable to swallow the oral pill as monkeypox symptoms include rashes and blisters in the mouth.
The week started off with a clinical bang for Verona Pharma, Kodiak, AstraZeneca and Daiichi Sankyo as these companies posted promising data in chronic obstructive pulmonary disease (COPD), lung cancer, and macular edema respectively.
The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday.
The Biden administration has decided to stretch out its limited supply of monkeypox vaccine by allowing a different method of injection that uses one-fifth as much per shot, the New York Times reported on Monday, citing senior officials familiar with the planning.